Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - FINANCIALPOST.COM - A La Une - 27/Aug 07:05
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China’s CDE have granted zongertinib Breakthrough Therapy Designation for patients with HER2-mutated NSCLC and who have received prior systemic therapy. Phase I trial data of a novel DLL3-targeting […]
Articles similaires
WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC
oncologynews.com.au - 13/Sep 02:26
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC
oncologynews.com.au - 13/Sep 02:26
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...
WCLC 2024: Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
oncologynews.com.au - 13/Sep 02:23
New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
FDA Puts MDMA for PTSD on Hold: No More Psychedelic Therapy?
cbdtesters.co - 12/Sep 08:30
The FDA has delayed the approval of MDMA-assisted therapy for PTSD, citing the need for additional safety and efficacy data. Is this the end for...
Les derniers communiqués
-
Four Seasons to Expand Saudi Arabian Portfolio Alongside Dar Al Omran Company with New Hotel in Madinah
Four Seasons Hotels and Resorts - 07/05/2024
-
Four Seasons Yachts Unveils Inaugural Itineraries to the Caribbean and Mediterranean and a First Look at its 95 Spectacular Suites
Four Seasons Hotels and Resorts - 27/03/2024
-
Visual 01Elevating Excellence: Four Seasons Embarks on the Next Stage of Strategic Global Growth
Four Seasons Hotels and Resorts - 22/01/2024